M/26/007 – Samsung Biologics/Human Genome

Transaction details

The proposed acquisition by Samsung Biologics America, Inc., a subsidiary of Samsung Biologics Co., Ltd. of sole control of Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline Holdings (Americas) Inc., has been notified to the Competition and Consumer Protection Commission.

Notification date Decision date
Wednesday January 28, 2026
Parties Involved Business activities
Samsung Biologics America, Inc.

Samsung Biologics America, Inc. is a subsidiary of Samsung Biologics Co., Ltd which is a company incorporated under the laws of the Republic of Korea and is engaged in biopharmaceutical manufacturing. Samsung Biologics Co., Ltd is a fully-integrated contract development and manufacturing organisation delivering end-to-end biologics to biotechnology and pharmaceutical companies.

Samsung Biologics Co., Ltd is part of the Samsung conglomerate and it's shareholders include Samsung C&T Corporation and Samsung Electronics Co. Limited. Samsung is a conglomerate active in a wide array of industries, including electronics, shipbuilding, engineering and insurance.

Human Genome Sciences, Inc

Human Genome Sciences, Inc. is a indirectly wholly owned subsidiary of GSK pie (formerly GlaxoSmithKline). Human Genome Sciences, Inc. is a biopharmaceutical company that manufactures bulk drug substance products.

Human Genome Sciences, Inc. operates two manufacturing plants in Maryland, the United States.

Economic sector Media merger
Manufacturing No
Submissions from third parties due by:
Phase 1 Phase 2
Wednesday, February 11, 2026
Current status: Active
Simplified Merger Notification
Authorised Officer Assigned Contact Details
Aodhán Frain

aodhanfrain@ccpc.ie

Media enquiries: communications@ccpc.ie

Return to Merger Notifications

Haven’t found what you’re looking for?